Private biotechs in Switzerland raised CHF833 million (US$1.002 billion) in 2024, driving an overall increase in capital investment in the sector to $3 billion, up from $2.4 billion in 2023.

Despite the uncertain macro environment created by the threat of reciprocal tariffs on goods into the U.S., some investors are still upbeat about the med tech sector. Even with changes at the HHS and disruption to product approvals throughout the FDA, venture capital investors remain cautiously optimistic.

Following last fall’s $1 billion development deal with Eli Lilly and Co., precision medicine company Haya Therapeutics SA has raised $65 million in a series A. It’s all part of increased validation from big pharmas that long noncoding RNAs, such as those being developed by Haya, have a strong future.

Safeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary endoluminal fecal bypass system, Colovac, which is placed in the colon following colorectal resection. The funds will be used to complete an investigational device exemption pivotal study and speed up preparation for commercial launch of the device.

Nuevocor Pte. Ltd. has closed a $45 million series B, enabling it to move lead gene therapy NVC-001 into the clinic in the treatment of an inherited form of cardiomyopathy.

Armatus Bio Inc.’s development of ARM-201, an AAV-delivered microRNA therapy for facioscapulohumeral muscular dystrophy (FSHD), has been boosted by a $3 million investment by Solve FSHD.